Analysis of efficacy and toxicity of thalidomine in 122 patients with multiple myeloma: Response of soft-tissue plasmacytomas [6]

Leukemia

Volumn 19, Issue 1, 2005, Pages 143-145

  Wu, K L ^a   Helgason, H H ^b   van der Holt, B ^a   Wijermans, P W ^c   Lokhorst, H M ^d   Smit, W M ^b   Sonneveld, P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; MELPHALAN; THALIDOMIDE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DEPRESSION; DIZZINESS; DOSE CALCULATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FOLLOW UP; HUMAN; LETTER; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTIPLE MYELOMA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PERIPHERAL NEUROPATHY; PLASMACYTOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN TINGLING; SOFT TISSUE CANCER; SOMNOLENCE; THROMBOEMBOLISM;

EID: 11844263905     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403568     Document Type: Letter

References (8)

1. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999, 341: 1565-1571.
2. Schey SA, Cavenagh J, Johnson R, Child JA, Oakervee H, Jones RW. An UK myeloma forum phase II study of thalidomide: long term follow-up and recommendations for treatment. Leukemia Res 2003; 27: 909-914.
3. Kumar S, Gertz MA, Dispenzieri A, Lacy MQ, Geyer SM, Iturria NL et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003; 78: 34-39.
4. Blade J, Perales M, Rosinol L, Tuset M, Montoto S, Esteve J et al. Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas. Br J Haematol 2001; 113: 422-424.
5. Rosinol L, Cibeira MT, Blade J, Esteve J, Aymerich M, Rozman M et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89: 832-836.
6. Biagi JJ, Mileshkin L, Grigg AP, Westerman DW, Prince HM. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. Bone Marrow Transplant 2001; 28: 1145-1150.
7. Ribas C, Colleoni G, Almeida M, Duch CR, Ohashi C, Segreto R et al. Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma. Acta Oncol 2004; 43 215-216.
8. Zangari M, Anaissie E, Barlogie B, Badros A, Desikan R, Gopal AV et al. increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.